Why the study?
It remains largely unknown how to risk-stratify patients with mitral valve prolapse who experience malignant ventricular arrhythmias and sudden cardiac death, and specific management recommendations are lacking.
Highlights the clinical challenges in risk stratification and management of malignant arrhythmic mitral valve prolapse presenting as sudden cardiac death.
Highlights SCD risk as MVP presentation; hypothesis-generating for risk stratification.
Mitral valve prolapse (MVP) is a common valvular disease, which may remain a benign condition for a long period of time. However, some patients experience malignant ventricular arrhythmias and sudden cardiac death (SCD). It is still largely unknown how to risk-stratify these patients, and no specific recommendations have been proposed to help the clinical decision-making. We present the case of a young man whose first clinical presentation was an out-of-hospital cardiac arrest and was subsequently diagnosed with MVP. We highlighted the possible risk factors for SCD and the challenges in the clinical management of these patients.
No takes yet. Share an insight, caveat, or question.
Yedidya et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: